What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
Nasdaq

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
Monthly Prescribing Reference

Tolebrutinib Misses Primary Endpoint in Phase 3 PPMS Study

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...
FierceBiotech

Immunic CEO says 'nobody should care at all' about missed primary endpoint in MS study

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive multiple sclerosis (PMS), but the New York biotech is pointing to other ...
Morningstar

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...
Business Insider

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...